LA 6-THIO-2'-DESOXYGUANOSINE (6-THIO-DG) ENTRAINE UN DYSFONCTIONNEMENT DES TELOMERES DEPENDANT DE LA TELOMERASE ET LA MORT CELLULAIRE DANS DES CELLULES CANCEREUSES RESISTANTES A DES THERAPIES
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM;THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
发明人:
SHAY, JERRY W.,ZHANG, GAO
申请号：
CA3025522
公开号：
CA3025522A1
申请日:
2017.05.26
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
The present disclosure provide for methods of using 6-thio-2'-deoxyguanosine (6-thio- dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.
